biostudies-literatureHung RJCTSAU.S. Army Medical ResearchNCATSFIS-FEDERNCATS NIH HHSWorld Health OrganizationNCRR NIH HHSFICYTMateriel Command ProgramDepartment of DefenseAsturiasNCI NIHCIHRNCRRMedical Research CouncilNCI NIH HHSVanderbilt UniversityUK BiobankCanadian Cancer Society Research Institute1607-1615https://www.ebi.ac.uk/biostudies/studies/S-EPMC7969419biostudies-literatureUnknown81(6)Lung cancer is the leading cause of cancer-related death globally. An improved risk stratification strategy can increase efficiency of low-dose CT (LDCT) screening. Here we assessed whether individual's genetic background has clinical utility for risk stratification in the context of LDCT screening. On the basis of 13,119 patients with lung cancer and 10,008 controls with European ancestry in the International Lung Cancer Consortium, we constructed a polygenic risk score (PRS) via 10-fold cross-validation with regularized penalized regression. The performance of risk model integrating PRS, including calibration and ability to discriminate, was assessed using UK Biobank data (<i>N</i> = 335,931). Absolute risk was estimated on the basis of age-specific lung cancer incidence and all-cause moCancer researchAssessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model.PMC7969419FIS-01/31010153006P20 RR018787UL1 TR000117U01 CA209414K07 CA172294FIS-07-BI060604P30 CA177558FICYT PB02-6723261P50 CA090578P20 CA090578020214S10 RR025141U01 CA063464MC_QA137853P30 CA076292R01 CA074386U19 CA148127MC_PC_17228U01 CA164973R35 CA197449UL1TR000445U01-CA063673UL1 TR000445U01 CA1674621S10RR025141-01P50 CA119997P01 CA033619R01 CA092824FIS-PI03-0365FICYT IB09-133001R01 CA063464U01-CA167462UM1 CA167462W81XWH-11-1-0781FDN 167273U01 CA063673U19 CA203654UM1 CA164973UM1-CA167462Zienolddiny SChatterjee NChristiani DCBrhane YAmos CIAldrich MCBojesen SEHung RJCaporaso NELazarus PWarkentin MTMcKay JDKiemeney LABrennan PTardon ABickeboller HChen CRisch AArnold SMRennert GAlbanes DLandi MTLam SMarchand LLJohansson MAndrew ASField JKLiu GSchabath MBfalseAssessing Lung Cancer Absolute Risk Trajectory Based on a Polygenic Risk Model.Lung cancer is the leading cause of cancer-related death globally. An improved risk stratification strategy can increase efficiency of low-dose CT (LDCT) screening. Here we assessed whether individual's genetic background has clinical utility for risk stratification in the context of LDCT screening. On the basis of 13,119 patients with lung cancer and 10,008 controls with European ancestry in the International Lung Cancer Consortium, we constructed a polygenic risk score (PRS) via 10-fold cross-validation with regularized penalized regression. The performance of risk model integrating PRS, including calibration and ability to discriminate, was assessed using UK Biobank data (<i>N</i> = 335,931). Absolute risk was estimated on the basis of age-specific lung cancer incidence and all-cause mo2021-01-01T00:00:00Z2021 Mar2026-06-04T04:31:32.188Z2022-02-11T10:53:54.445ZS-EPMC79694193347289010.1158/0008-5472.CAN-20-123710.1158/0008-5472.can-20-1237